Amerise Biosciences Limited

As of June 30, 2026, Amerise Biosciences Limited carries a market capitalization of 54.18M, placing it among publicly traded companies globally. Its enterprise value stands at 54.18M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Amerise Biosciences Limited has 66.07M shares outstanding.

As of the close on October 22, 2026, Amerise Biosciences Limited's stock has gained approximately 47.27% over the past 52 weeks. The 50-day moving average sits at 0.82, while the 200-day moving average is 0.75.

Over the twelve months ended June 30, 2026, Amerise Biosciences Limited generated - - in revenue and converted that into -527,000.00 in net income, yielding earnings per share of -0.01. EBITDA reached -1.65M, while operating income came in at -1.65M.